Get the Stockscreener App
37.22
3.39%
1.22
After Hours:
36.48
-0.74
-1.99%
Vtv Therapeutics Inc stock is traded at $37.22, with a volume of 75,944.
It is up +3.39% in the last 24 hours and up +20.03% over the past month.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
See More
Previous Close:
$36.00
Open:
$37.4575
24h Volume:
75,944
Relative Volume:
3.24
Market Cap:
$146.57M
Revenue:
$17,000
Net Income/Loss:
$-23.87M
P/E Ratio:
-11.93
EPS:
-3.12
Net Cash Flow:
$-22.03M
1W Performance:
-5.34%
1M Performance:
+20.03%
6M Performance:
+103.28%
1Y Performance:
+117.66%
1-Day Range:
$34.98
$38.96
1-Week Range:
$34.40
$39.66
52-Week Range:
$14.00
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Name
Vtv Therapeutics Inc
Sector
Industry
Phone
336-841-0300
Address
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
37.22 | 141.77M | 17,000 | -23.87M | -22.03M | -3.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Jan-05-26 | Initiated | TD Cowen | Buy |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| May-30-19 | Initiated | H.C. Wainwright | Buy |
| Apr-10-18 | Downgrade | Stifel | Buy → Hold |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Initiated | Northland Capital | Outperform |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Sep-04-15 | Initiated | Canaccord Genuity | Buy |
| Aug-24-15 | Initiated | Piper Jaffray | Overweight |
| Aug-24-15 | Initiated | Stifel | Buy |
View All
Vtv Therapeutics Inc Stock (VTVT) Latest News
vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737 - Yahoo Finance
Discipline and Rules-Based Execution in VTVT Response - Stock Traders Daily
VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst - Seeking Alpha
VTVT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 61.2% in February - MarketBeat
VTVT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VTVT PE Ratio & Valuation, Is VTVT Overvalued - Intellectia AI
vTv Therapeutics Highlights Cadisegliatin Progress and Financial Strength - TipRanks
vTv Therapeutics posts updated investor presentation highlighting Phase 3 cadisegliatin readout and $118.5M liquidity - TradingView
vTv Therapeutics (VTVT) spotlights cadisegliatin Phase 3 and cash runway - Stock Titan
VTVT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Quarterly Earnings: Can US Physical Therapy Inc deliver consistent EPS growth2025 Earnings Impact & Breakout Confirmation Trade Signals - baoquankhu1.vn
What are analysts’ price targets for vTv Therapeutics Inc.2025 Retail Activity & Short-Term Trading Opportunity Alerts - mfd.ru
Can vTv Therapeutics Inc. sustain earnings growthProfit Target & Long-Term Safe Investment Plans - mfd.ru
vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Stock Analysis: What are analysts price targets for vTv Therapeutics IncMarket Activity Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
vTv Therapeutics (VTVT) CFO granted 44,969 stock options at $36.92 - Stock Titan
Behavioral Patterns of VTVT and Institutional Flows - Stock Traders Daily
What’s next for vTv Therapeutics Inc. stockMarket Trend Report & AI Powered Buy/Sell Recommendations - mfd.ru
Why vTv Therapeutics Inc. stock could see breakout soonJuly 2025 Fed Impact & High Accuracy Swing Trade Signals - mfd.ru
vTv Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Type 1 diabetes drug developer vTv set for two investor conferences - Stock Titan
Will vTv Therapeutics Inc. stock recover after earningsShort Setup & Stock Portfolio Risk Management - mfd.ru
Is vTv Therapeutics Inc.’s ROE strong enoughQuarterly Growth Report & Smart Allocation Stock Reports - mfd.ru
Aug Retail: Does vTv Therapeutics Inc have strong fundamentalsEarnings Overview Report & Stepwise Swing Trade Plans - baoquankhu1.vn
(VTVT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Q1 EPS Forecast for vTv Therapeutics Increased by Analyst - Defense World
HC Wainwright Boosts Earnings Estimates for vTv Therapeutics - MarketBeat
Will vTv Therapeutics Inc outperform the market in YEARQuarterly Trade Report & Stepwise Trade Signal Guides - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS) - The Globe and Mail
vTv Therapeutics expands HPP737 license agreement with Newsoara Biopharma By Investing.com - Investing.com India
vTv Therapeutics expands HPP737 license agreement with Newsoara Biopharma - Investing.com Australia
vTv Therapeutics Expands Global HPP737 Rights with Newsoara - TipRanks
vTv Therapeutics Signs License Agreement Amendment With Newsoara Biopharma - TradingView
vTv expands Newsoara license deal for PDE4 inhibitor to global rights - Investing.com India
VTVT Expands Global Rights Agreement for PDE4 Inhibitor - GuruFocus
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737 - GlobeNewswire
Analysts Set vTv Therapeutics Inc. (NASDAQ:VTVT) Price Target at $55.25 - Defense World
VIX Spike: Is vTv Therapeutics Inc likely to announce a buybackMarket Volume Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
vTv Therapeutics Inc. (NASDAQ:VTVT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Published on: 2026-01-29 06:19:41 - baoquankhu1.vn
VTVT: BTIG Raises Price Target to $49.00, Maintains Buy Rating | - GuruFocus
How (VTVT) Movements Inform Risk Allocation Models - Stock Traders Daily
vTv Therapeutics (NASDAQ:VTVT) Upgraded to Strong-Buy at Roth Mkm - MarketBeat
This MasTec Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Roth Capital Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - Nasdaq
Roth/MKM initiates coverage on vTv Therapeutics stock with Buy rating - Investing.com Canada
Roth Capital Initiates Coverage on VTVT with a 'Buy' Rating | VT - GuruFocus
Buyout Rumor: Does vTv Therapeutics Inc have declining or rising EPSWeekly Gains Summary & Verified Momentum Stock Alerts - baoquankhu1.vn
Published on: 2026-01-19 16:04:02 - baoquankhu1.vn
Vtv Therapeutics Inc Stock (VTVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):